Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476047 | 1.00 | TSHR (0.40) | TSHRTDP1ALOX15CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL9300845 | 0.98 | TSHR (0.39) | TSHRTDP1ALOX15CHRM2CHRM4 | |
| SCHEMBL9300841 | 0.79 | TSHR (0.39) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10475855 | 0.79 | ALDH1A1 (0.38) | TSHR | |
| SCHEMBL15284985 | 0.78 | TSHR (0.42) | TSHRTDP1ALOX15CHRM2CHRM4 | |
| SCHEMBL15284981 | 0.78 | TSHR (0.42) | TSHRTDP1ALOX15CHRM2CHRM4 | |
| SCHEMBL27996325 | 0.76 | TSHR (0.40) | TSHRALOX15CHRM2CHRM4CHRM1 | |
| SCHEMBL6931998 | 0.75 | SLC1A3 (0.36) | — | |
| SCHEMBL6932001 | 0.75 | SLC1A3 (0.36) | — | |
| SCHEMBL19663109 | 0.74 | ACHE (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-108912111-B | Compounds and pharmaceutical compositions | 赛克里翁治疗有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3660013-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20170137439-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136019-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160375022-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-0592669-B1 | OPTICALLY ACTIVE TRIFLUOROLACTIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORP (JP) | 1998-01-28 | — | — | EP | disclosed |
| US-5665270-A | Optically active trifluorolactic acid derivative and liquid crystal composition | CHISSO CORPORATION (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0592669-A1 | OPTICALLY ACTIVE TRIFLUOROLACTIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20170137439-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20170136019-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20160375022-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
| US-20200316065-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | TSHR 1687/4885TDP1 711/4885ALOX15 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.